Annexin Expression in Cholangiocarcinoma, and Metastatic Pancreatic Ductal Adenocarcinoma “Is it be Helpful for Differential Diagnosis of These Tumors in the Liver?”

Background & Objective: Differential diagnosis between cholangiocarcinoma (CCA) and metastatic pancreatic ductal adenocarcinoma (PDA) in the liver is difficult so far, no specific immunohistochemical marker reported to differentiate these two tumors. Considering existing literature, level of expression Annexins (Annexin A1, 10 13) have been studied for differential tumors by molecular methods promising results reported. Therefore, this study, we tried investigate value three CCA PDA liver.Methods: The articles that research subject years (2009-2019), including 45 cases 50 were evaluated considering presence or absence AnnexinA1 (ANXA1), Annexin A10 (ANXA10) A13 (ANXA13) immunohistochemistry, investigated.Results Conclusion: This study showed, ANXA1 was positive both CCA, ANXA10 ~60% ~40% cases, ANXA13 mostly negative groups. best sensitivity found cytoplasmic nuclear (80% 84%, respectively) distinguish from vice versa. specificity observed CCA. Also, had PDA. Our investigations showed that, probably can classify correctly, but it cannot discriminate fair apparently a high help narrow-down diagnoses.